Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Oxid Med Cell Longev ; 2018: 5042428, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30327714

RESUMEN

BACKGROUND: D-tagatose is an isomer of fructose and is ~90% as sweet as sucrose with less caloric value. Nowadays, D-tagatose is used as a nutritive or low-calorie sweetener. Despite clinical findings suggesting that D-tagatose could be beneficial in subjects with type 2 diabetes, there are no experimental data comparing D-tagatose with fructose, in terms of metabolic derangements and related molecular mechanisms evoked by chronic exposure to these two monosaccharides. MATERIALS AND METHODS: C57Bl/6j mice were fed with a control diet plus water (CD), a control diet plus 30% fructose syrup (L-Fr), a 30% fructose solid diet plus water (S-Fr), a control diet plus 30% D-tagatose syrup (L-Tg), or a 30% D-tagatose solid diet plus water (S-Tg), during 24 weeks. RESULTS: Both solid and liquid fructose feeding led to increased body weight, abnormal systemic glucose homeostasis, and an altered lipid profile. These effects were associated with vigorous increase in oxidative markers. None of these metabolic abnormalities were detected when mice were fed with both the solid and liquid D-tagatose diets, either at the systemic or at the local level. Interestingly, both fructose formulations led to significant Advanced Glycation End Products (AGEs) accumulation in mouse hearts, as well as a robust increase in both myocardial AGE receptor (RAGE) expression and NF-κB activation. In contrast, no toxicological effects were shown in hearts of mice chronically exposed to liquid or solid D-tagatose. CONCLUSION: Our results clearly suggest that chronic overconsumption of D-tagatose in both formulations, liquid or solid, does not exert the same deleterious metabolic derangements evoked by fructose administration, due to differences in carbohydrate interference with selective proinflammatory and oxidative stress cascades.


Asunto(s)
Fructosa/farmacología , Hexosas/farmacología , Miocardio/metabolismo , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Animales , Corazón/efectos de los fármacos , Masculino , Síndrome Metabólico/inducido químicamente , Síndrome Metabólico/metabolismo , Ratones , Ratones Endogámicos C57BL , Distribución Aleatoria , Transducción de Señal/efectos de los fármacos , Edulcorantes/farmacología
2.
Thromb Haemost ; 102(5): 837-45, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19888517

RESUMEN

Heparin and low molecular weight heparins may reduce brain damage evoked by ischaemia/reperfusion (I/R) injury, although their use is hampered by the risk of haemorrhage. Chemical and enzymatic modifications of K5 polysaccharide have shown the possibility to produce heparin-like compounds with low anticoagulant activity and strong anti-inflammatory effects. Using a rat model of transient cerebral I/R, we investigated the effects of an epimerised N-,O-sulfated K5 polysaccharide derivative, K5-N,OSepi, on the infarct size, motor activity and injury caused by ischaemia (30 min) and reperfusion. Reperfusion was allowed for 60 min or 1-5 days. Rats reperfused for 5 days showed an infarct volume of 30.7 +/- 3.1% and K5-N,OSepi (0.1-1 mg/kg) caused dose-dependent reduction in infarct size (maximum at 1 mg/kg: 13.1 +/- 2.1% infarct volume). This effect was associated with a significant improvement in motor performance. In the rat hippocampus, one of the brain areas most sensitive to I/R injury, I/R induced a robust increase in myeloperoxidase (MPO) activity, a marker of neutrophil infiltration, that was halved by K5-N,OSepi administration (66.38 +/- 7.75 microU MPO/tissue g, 30.78 +/- 5.67 microU MPO/tissue g, respectively). K5-N,OSepi drastically reduced the expression of cyclooxygenase-2, inducible-nitric-oxide-synthase and intercellular-adhesion-molecule-1. I/R-induced activation of nuclear factor-kB was attenuated by drug treatment. Furthermore, K5-N,OSepi administration was associated with a significant modulation of apoptosis markers, such as Bid and Bcl-2. In conclusion, the results demonstrated that the sulfated semi-synthetic K5 derivative K5-N,OSepi protects the brain against I/R injury by disrupting multiple levels of the apoptotic and inflammatory cascade, including inhibition of NF-kappaB activation.


Asunto(s)
Antiinflamatorios/uso terapéutico , Anticoagulantes/uso terapéutico , Isquemia Encefálica/tratamiento farmacológico , Polisacáridos/uso terapéutico , Daño por Reperfusión/tratamiento farmacológico , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/farmacología , Anticoagulantes/síntesis química , Anticoagulantes/farmacología , Apoptosis/efectos de los fármacos , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/biosíntesis , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/genética , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/prevención & control , Isquemia Encefálica/etiología , Isquemia Encefálica/patología , Quimiotaxis de Leucocito/efectos de los fármacos , Ciclooxigenasa 2/biosíntesis , Ciclooxigenasa 2/genética , Evaluación Preclínica de Medicamentos , Hipocampo/irrigación sanguínea , Hipocampo/efectos de los fármacos , Hipocampo/patología , Inflamación/prevención & control , Molécula 1 de Adhesión Intercelular/biosíntesis , Molécula 1 de Adhesión Intercelular/genética , Masculino , Neutrófilos/enzimología , Óxido Nítrico Sintasa de Tipo II/biosíntesis , Óxido Nítrico Sintasa de Tipo II/genética , Polisacáridos/síntesis química , Polisacáridos/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Proteínas Proto-Oncogénicas c-bcl-2/genética , Desempeño Psicomotor/efectos de los fármacos , Distribución Aleatoria , Ratas , Ratas Wistar , Daño por Reperfusión/patología , Factor de Transcripción ReIA/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA